EU Falsified Medicines Directive ‘Not Working’ In Northern Ireland
Executive Summary
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”
You may also be interested in...
Medicines ‘Must Not Fall Off The Radar’ In Northern Ireland Protocol Talks
As heated discussions continue on the future of the protocol that keeps Northern Ireland within the EU’s single market, the UK government has been urged to ensure concerns over medicines supply are addressed before “rushing to get a deal done.”
Industry Warns Of New Post-Brexit ‘Cliff Edge’ For Medicines Supply To Northern Ireland
The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.